Lv1
60 积分 2024-02-22 加入
Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer
2天前
已完结
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
2天前
已完结
Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial
2天前
已完结
Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer
1个月前
已完结
Impact of EGFR exon 19 deletion subtypes on clinical outcomes in EGFR-TKI-Treated advanced non-small-cell lung cancer
1个月前
已完结
Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis
3个月前
已完结
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer
3个月前
已完结
Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2/3 DYNAMIC-III trial
4个月前
已完结
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer
6个月前
已完结
Comprehensive evaluation of BRCA1/2 variant interpretation ability among laboratories in China
9个月前
已完结
皖公网安备34019202002308
